Moderna (MRNA) Tax Provisions (2018 - 2026)

Moderna (MRNA) has 9 years of Tax Provisions data on file, last reported at $9.0 million in Q1 2026.

• Tax Provisions for Q1 2026 came in at $9.0 million, up 28.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.0 million (up 214.29% YoY), and the FY2025 annual result was $54.0 million, up 217.39% from the prior year.
• Tax Provisions fell to $9.0 million in Q1 2026 per MRNA's latest filing, from $27.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $1.7 billion in Q3 2023 and troughed at -$384.0 million in Q1 2023.
• A 5-year average of $125.1 million and a median of $9.5 million in 2024 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2022 and 2023: Tax Provisions surged 1366.67% in 2022, then plunged 233.21% in 2023.
• A 5-year view of Tax Provisions shows it stood at $190.0 million in 2022, then plunged by 177.37% to -$147.0 million in 2023, then jumped by 56.46% to -$64.0 million in 2024, then jumped by 142.19% to $27.0 million in 2025, then sank by 66.67% to $9.0 million in 2026.
• Business Quant data shows MRNA's Tax Provisions at $9.0 million in Q1 2026, $27.0 million in Q4 2025, and $13.0 million in Q3 2025.